Company research / TARA

Protara Therapeutics, Inc. (TARA)

CIK 0001359931 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Fiscal year ends Dec 31

Key ratios (year ended 2025-12-31)

-29.2%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-11

Headquarters locality: Waltham · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
R&D Expense$53.23M$42.63M$31.70M$24.99M$16.81M$21.09M$11.98M$3.88M$11.85M$21.69M$18.87M
Operating Income-$76.79M-$64.55M-$49.15M-$43.61M-$67.06M-$47.49M-$34.44M-$7.83M-$21.37M-$30.36M-$28.70M
Depreciation & Amortizationn/an/an/an/an/an/an/an/an/an/a$123.0K
EBITDAn/an/an/an/an/an/an/an/an/an/a-$28.58M
Net Income-$70.02M-$57.44M-$44.60M-$40.42M-$65.95M-$47.25M-$33.98M-$7.83M-$20.73M-$29.96M-$28.53M
EPS (Diluted)n/a-$1.34-$2.17-$3.57-$5.86-$4.21n/an/an/an/an/a
Total Assets$176.09M$209.47M$181.45M$78.95M$113.29M$172.60M$203.16M$1.22M$23.52M$43.98M$43.52M
Total Liabilities$14.78M$13.06M$14.32M$10.63M$11.21M$10.68M$3.91M$3.35M$3.08M$9.24M$5.08M
Shareholders' Equity$161.31M$196.41M$167.13M$68.32M$102.08M$161.91M$199.24M-$2.13M$20.44M$34.74M$38.44M
Cash & Equivalents$17.08M$49.66M$162.80M$39.59M$24.13M$35.72M$168.60M$564.0K$19.37M$21.17M$36.39M
Operating Cash Flow-$66.13M-$56.37M-$35.81M-$37.56M-$26.46M-$34.50M-$23.41M-$5.01M-$23.23M-$22.35M-$23.69M
Capital Expenditures$360.0K$94.0K$63.0K$45.0K$120.0K$596.0K$884.0K$475.0K$119.0K$35.0K$271.0K
Free Cash Flow-$66.49M-$56.46M-$35.87M-$37.60M-$26.58M-$35.10M-$24.29M-$5.49M-$23.35M-$22.39M-$23.96M
Share Repurchasesn/an/an/a$91.0K$90.0K$228.0Kn/an/an/an/an/a
Shares Outstanding59.08M53.59M35.04M11.36M11.27M11.24M11.21M2.63M481.1K17.67M16.60M
Weighted Average Diluted Sharesn/a42.84M20.59M11.33M11.26M11.23Mn/an/an/an/an/a
EPS (Basic)n/a-$1.34-$2.17-$3.57-$5.86-$4.21n/an/an/an/an/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView